Cargando…

A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis

OBJECTION: To explore the effects of combinations of antiangiogenic agents and chemotherapy agents on non-small cell lung cancer (NSCLC) patients and indirectly compare the therapeutic effect of Endostar combined with chemotherapy and bevacizumab combined with chemotherapy on NSCLC. METHODS: We sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yimin, Yi, Yonglin, Lin, Anqi, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653849/ https://www.ncbi.nlm.nih.gov/pubmed/33292249 http://dx.doi.org/10.1186/s12935-020-01639-4

Ejemplares similares

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011)

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
por: Sheng, Jin, et al.
Publicado: (2015)

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
por: Dai, Jiali, et al.
Publicado: (2023)

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
por: Vo, Kieuhoa T., et al.
Publicado: (2016)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy
por: Yonucu, Sirin, et al.
Publicado: (2017)

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis
por: Li, Jiaqi, et al.
Publicado: (2022)

CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Yi, Yonglin, et al.
Publicado: (2022)

Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects
por: Zhao, Xiaoliang, et al.
Publicado: (2016)

Advances in antiangiogenic treatment of small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2017)

Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis
por: Srivastava, Akanksha, et al.
Publicado: (2021)

Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients
por: Lin, Anqi, et al.
Publicado: (2022)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer
por: Chen, Jin-Hua, et al.
Publicado: (2018)

Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
por: Adamcic, Una, et al.
Publicado: (2012)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
por: Yao, Zifu, et al.
Publicado: (2022)

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
por: Ma, Ke, et al.
Publicado: (2023)

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
por: Pozzi, Ambra, et al.
Publicado: (2008)

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
por: Beal, Kathryn, et al.
Publicado: (2011)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis
por: Pan, Xin-Bin, et al.
Publicado: (2022)

Editorial: Are natural products, used as antitumoral/antiangiogenic agents, less toxic than synthetic conventional chemotherapy?
por: Nunez, Cecilia Veronica, et al.
Publicado: (2022)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis
por: Yi, SuYi, et al.
Publicado: (2017)

The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis
por: Lei, Xuefen, et al.
Publicado: (2017)

Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
por: Caminha, Raquel D’Aquino Garcia, et al.
Publicado: (2019)

Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma: A protocol for systematic review and network meta-analysis
por: Li, Runting, et al.
Publicado: (2020)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
por: Xu, Yinghui, et al.
Publicado: (2022)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
por: Chen, Fei, et al.
Publicado: (2020)

Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
por: Xuan, Tian-Tian, et al.
Publicado: (2022)

Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI
por: Chen, Feng, et al.
Publicado: (2012)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis: Erratum
Publicado: (2017)

Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Ma, Jie-Tao, et al.
Publicado: (2021)

Monitoring Treatment Efficacy of Antiangiogenic Therapy Combined With Hypoxia-Activated Prodrugs Online Using Functional MRI
por: Ma, Mengjie, et al.
Publicado: (2021)

A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer
por: Ge, Long, et al.
Publicado: (2017)

Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer
por: Wang, Zhizhen, et al.
Publicado: (2023)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_p7idbmg6eh5enp7d9mt8terev9